Venetoclax induces deep and durable MRD-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.

B-cell prolymphocytic leukaemia (B-PLL) is an aggressive B-cell lymphoproliferative disease with few clinically proven targeted treatments. Due to the rarity of the condition, there is a paucity of clinical trial data, and none that involve targeted inhibitors. We present a unique case of relapsed refractory B-PLL treated to a sustained MRD-negative remission with venetoclax monotherapy, to add to the current evidence base and rationale for future studies using BCL-2 inhibitors in B-PLL.